This is promotional content, intended for UK healthcare professionals only. This webpage has been developed and funded by the Bristol-Myers Squibb / Pfizer Alliance.
Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.
This section addresses the treatment of patients with confirmed VTE, including:
Anticoagulation for the management of VTE
Initial management of a confirmed VTE
DOACs for the treatment of VTE and prevention of recurrent VTE
Efficacy and safety of DOACs
Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via firstname.lastname@example.org or 0800 731 1736 (United Kingdom).
DOAC=Direct-acting Oral AnticoagulantDVT=Deep Vein ThrombosisMHRA=Medicines and Healthcare products and Regulatory AgencyPE=Pulmonary EmbolismVTE=Venous Thromboembolism
Job code: 432-GB-2100110
Date of preparation: September 2021
YOU ARE ABOUT TO LEAVE THIS WEBSITE
This link takes you to a third party website that is part of the Bristol-Myers Squibb Group and Pfizer Group. The Alliance (Bristol Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it. If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.